News & Updates

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023

Anti-obesity therapies go beyond weight loss

19 Jul 2023 by

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Anti-obesity therapies go beyond weight loss

19 Jul 2023

Phase III data support long-term efficacy of TAF against HBV

18 Jul 2023 by

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).

Phase III data support long-term efficacy of TAF against HBV

18 Jul 2023

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

Mepolizumab does not appear to reduce the symptoms of dysphagia as compared with placebo in the treatment of individuals with eosinophilic oesophagitis (EoE), although the drug helps reduce eosinophil counts and endoscopic severity, according to a study.

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023 by

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

10 Jul 2023

A phenome-wide association study (pheWAS) has found known and potentially new risk factors for gastrointestinal (GI) dysfunction in systemic sclerosis (SSc), which include drug classes such as opioid, antimuscarinic, and endothelin receptor antagonist, and antinuclear antibodies (ANAs) subgroup.

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

10 Jul 2023

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023 by

The ileal bile acid transporter (IBAT) inhibitor maralixibat appears to quell itching and reduce serum bile acid concentration in children with progressive familial intrahepatic cholestasis (PFIC), while having a tolerable safety profile, according to data from the phase III MARCH-PFIC trial said to be the largest to date.

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023 by

In a pooled analysis of two long-term paediatric extension trials evaluating short bowel syndrome-associated intestinal failure (SBS-IF), the glucagon-like peptide-2 analogue teduglutide (TED) demonstrated a safety profile that aligned with previous data.

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023

$Faecal transplant helps teens with refractory IBS$

Faecal transplant helps teens with refractory IBS

29 Jun 2023 by

For adolescents with treatment-refractory irritable bowel syndrome (IBS), faecal microbiota transplantation (FMT) is safe and beneficial, easing abdominal pain and improving health-related quality of life, according to a study presented at ESPGHAN 2023.

Faecal transplant helps teens with refractory IBS

29 Jun 2023

PPI use ups mortality risk in ICU patients

29 Jun 2023

Use of proton pump inhibitors (PPIs) for the prevention of stress ulceration appears to elevate the risk of mortality in patients admitted to the intensive care unit (ICU), reveals a study.

PPI use ups mortality risk in ICU patients

29 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Anti-obesity therapies go beyond weight loss

Anti-obesity therapies go beyond weight loss

Phase III data support long-term efficacy of TAF against HBV

Phase III data support long-term efficacy of TAF against HBV

Mepolizumab does little to improve dysphagia symptoms

Mepolizumab does little to improve dysphagia symptoms

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

Another IBAT inhibitor makes its case in large PFIC trial

Another IBAT inhibitor makes its case in large PFIC trial

Long-term data support teduglutide safety for SBS-IF

Long-term data support teduglutide safety for SBS-IF

Faecal transplant helps teens with refractory IBS

Faecal transplant helps teens with refractory IBS

PPI use ups mortality risk in ICU patients

PPI use ups mortality risk in ICU patients